Updated 2011 review of T2DM treatment advances with GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide), DPP-4 inhibitors, and emerging combination approaches dominating new drug development.
Key findingUpdated 2011 review of T2DM treatment advances with GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide), DPP-4 inhibitors, and emerging com
What the researchers found
Updated 2011 review of T2DM treatment advances with GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide), DPP-4 inhibitors, and emerging combination approaches dominating new drug development.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Advances in the treatment of type 2 diabetes mellitus.
American journal of therapeutics, 18(2), 117-52
Citation
Israili, Zafar H. (2011). Advances in the treatment of type 2 diabetes mellitus.. American journal of therapeutics, 18(2), 117-52. https://doi.org/10.1097/MJT.0b013e3181afbf51